Sayre Therapeutics
Founded in 2015, Sayre Therapeutics is a healthcare company driven by a mission to transform patient care through innovative research, strategic partnerships, and regulatory expertise. With 25 years of global leadership experience across pharmaceuticals, diagnostics, and medical devices, the company specializes in delivering cutting-edge, cost-effective therapies for life-threatening and rare diseases, primarily across India, South Asia, and Southeast Asia. Sayre Therapeutics aims to become Asia’s healthcare company of choice by providing high-quality, novel medical solutions for complex diseases, emphasizing access, affordability, and societal impact.
Industries
Nr. of Employees
small (1-50)
Sayre Therapeutics
Products
Rasburicase injection (rasburicase, 1.5 mg)
Intravenous enzyme therapy indicated for prevention and treatment of tumor lysis syndrome.
Pegfilgrastim prefilled syringe (6 mg)
Long‑acting pegylated granulocyte‑colony stimulating factor for prevention of chemotherapy‑induced neutropenia.
PEG L‑Asparaginase injection (3750 IU/5 mL)
PEGylated L‑asparaginase formulation used in multi‑agent chemotherapy regimens for acute lymphoblastic leukemia, including in patients hypersensitive to native asparaginase.
Carfilzomib for injection (60 mg/vial)
Proteasome inhibitor antineoplastic agent indicated for relapsed or refractory multiple myeloma as monotherapy or in combination regimens.
Tilmanocept radiopharmaceutical for lymphatic mapping (Technetium Tc‑99m formulation)
Radiopharmaceutical used for targeted lymphatic mapping to guide sentinel lymph node biopsy in breast, head & neck cancers and melanoma.
Image‑guided cryoablation system (clinical implementation support)
Clinical deployment and procedural support for cryoablation systems used in percutaneous or laparoscopic tumor ablation under imaging guidance.
Rasburicase injection (rasburicase, 1.5 mg)
Intravenous enzyme therapy indicated for prevention and treatment of tumor lysis syndrome.
Pegfilgrastim prefilled syringe (6 mg)
Long‑acting pegylated granulocyte‑colony stimulating factor for prevention of chemotherapy‑induced neutropenia.
PEG L‑Asparaginase injection (3750 IU/5 mL)
PEGylated L‑asparaginase formulation used in multi‑agent chemotherapy regimens for acute lymphoblastic leukemia, including in patients hypersensitive to native asparaginase.
Carfilzomib for injection (60 mg/vial)
Proteasome inhibitor antineoplastic agent indicated for relapsed or refractory multiple myeloma as monotherapy or in combination regimens.
Tilmanocept radiopharmaceutical for lymphatic mapping (Technetium Tc‑99m formulation)
Radiopharmaceutical used for targeted lymphatic mapping to guide sentinel lymph node biopsy in breast, head & neck cancers and melanoma.
Image‑guided cryoablation system (clinical implementation support)
Clinical deployment and procedural support for cryoablation systems used in percutaneous or laparoscopic tumor ablation under imaging guidance.
Services
Local study design, site coordination, protocol development, and execution of clinical studies with integration of QoL and health‑economic endpoints.
Regulatory strategy, dossier preparation, local submissions and facilitation of approvals and post‑marketing obligations across India and South Asia.
End‑to‑end commercialization including KOL engagement, territory sales, scientific promotion, and market‑access planning for niche therapeutics.
Introduces and distributes molecular and companion diagnostics through partnerships with international diagnostics providers and coordinates sample logistics.
Provides medical education, scientific content development, training for field teams, and support for investigator‑initiated studies and publications.
Regional distribution and supply of biosimilars and specialty injectable therapies sourced from certified manufacturing partners.
Local study design, site coordination, protocol development, and execution of clinical studies with integration of QoL and health‑economic endpoints.
Regulatory strategy, dossier preparation, local submissions and facilitation of approvals and post‑marketing obligations across India and South Asia.
End‑to‑end commercialization including KOL engagement, territory sales, scientific promotion, and market‑access planning for niche therapeutics.
Introduces and distributes molecular and companion diagnostics through partnerships with international diagnostics providers and coordinates sample logistics.
Provides medical education, scientific content development, training for field teams, and support for investigator‑initiated studies and publications.
Regional distribution and supply of biosimilars and specialty injectable therapies sourced from certified manufacturing partners.
Expertise Areas
- Clinical trial management in India and South Asia
- Regulatory strategy and product registration (India/South Asia)
- Commercialization and market access for niche oncology and rare disease therapies
- Medical affairs and KOL engagement
Key Technologies
- Molecular diagnostics
- Next‑generation diagnostic platforms
- Radiopharmaceuticals for sentinel lymph node mapping
- Image‑guided cryoablation
News & Updates
The company establishes a program for access to Daunoxome in India, expanding treatment options for patients.
The company partners for the distribution of Lutrate Depot across multiple South Asian countries.
A collaboration to commercialize CGIs proprietary tissue-of-origin test in India and South Asia.
Sayre Therapeutics raised USD 8 million in two funding rounds to support its growth and research initiatives.
The company establishes a program for access to Daunoxome in India, expanding treatment options for patients.
The company partners for the distribution of Lutrate Depot across multiple South Asian countries.
A collaboration to commercialize CGIs proprietary tissue-of-origin test in India and South Asia.
Sayre Therapeutics raised USD 8 million in two funding rounds to support its growth and research initiatives.